+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cariprazine"

Major Depressive Disorder Global Market Report 2024 - Product Thumbnail Image

Major Depressive Disorder Global Market Report 2024

  • Report
  • January 2024
  • 175 Pages
  • Global
From
Treatment Resistant Depression - Pipeline Insight, 2024 - Product Thumbnail Image

Treatment Resistant Depression - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Bipolar Depression - Pipeline Insight, 2024 - Product Thumbnail Image

Bipolar Depression - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
REAGILA Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

REAGILA Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • July 2023
  • 30 Pages
  • Global
From
From
United States VRAYLAR Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

United States VRAYLAR Market Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • United States
From
VRAYLAR, Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

VRAYLAR, Emerging Drug Insight and Market Forecast - 2032

  • Report
  • August 2022
  • 30 Pages
  • Global
From
From
Drug Overview: Vraylar - Product Thumbnail Image

Drug Overview: Vraylar

  • Report
  • April 2018
  • 38 Pages
  • Global
From
  • 14 Results (Page 1 of 1)
Loading Indicator

Cariprazine is a medication used to treat mental disorders such as schizophrenia and bipolar disorder. It is a dopamine receptor partial agonist, meaning it binds to dopamine receptors in the brain and activates them to a lesser degree than dopamine itself. Cariprazine is thought to work by restoring the balance of certain natural substances in the brain, such as dopamine and serotonin. It is available in both oral and injectable forms. Cariprazine is generally well-tolerated and has fewer side effects than other antipsychotic medications. Common side effects include nausea, headache, insomnia, and restlessness. It is important to note that cariprazine can cause serious side effects, such as an increased risk of death in elderly people with dementia-related psychosis. Cariprazine is a relatively new medication and is not yet widely available. It is currently approved for use in the United States, Canada, and several European countries. Some companies in the Cariprazine market include Gedeon Richter, Allergan, and Sunovion Pharmaceuticals. Show Less Read more